SNBL mending lab issues, while entangled with animal welfare issues in Israel
Almost two years after receiving an FDA warning letter citing 9 violations at its Everett, WA, laboratory, SNBL USA announced that it remedied 7 of them.
SPECIAL REPORT FROM FIERCEPHARMA
Top 10 Best-selling Cancer Drugs in 2011By Tracy StatonSLIDESHOW
Check the pulse of biotech IT in BostonBy Ryan McBride
TOP HEADLINES
Top Story
Covance's AZ lab closure to result in 130 lost jobs
Covance ($CVD) will close its $100 million Chandler, AZ, laboratory by year's end, a Covance spokeswoman tells FierceCRO, meaning the loss of 130 jobs.
Home drug delivery considered a 'key initiative' for Marken
Why go to the clinical trial, when you could bring the trial home to you? Offering a home delivery service for clinical subjects is a concept supply chain service provider Marken is looking at possibly using, as an Outsourcing-Pharma story shows.
Patient recruitment should be a greater priority, drugmakers say in survey
A survey of conducted by market research firm Industry Standard Research shows that nearly 90% of surveyed drugmakers would prefer reaching patient recruitment goals at least 10% faster over cutting Phase II or Phase III trial costs 20%.
BASi trims lab costs to recoup losses from first half of 2012
The Indiana CRO will have to reconfigure some of its lab operations in an effort to recoup losses, according to its second-quarter report.
Quanticate looks to India to expand ops, despite national controversy
The move reinforces the CRO's commitment to working in the country, despite controversy surrounding India's clinical and pharma handlings.
AMRI sees Q1 drops, but maintains positive financial outlook for 2012
As Albany Molecular Research ($AMRI) progresses into 2012, it is driven to recoup revenue it lost out on in the first quarter.
From Our Sister Sites
The Danvers, MA device company ended its 2012 fiscal year in the black, with record revenue in hand, thanks in large part to its Impella pumps, which are designed to aid an ailing heart rather than replace it.
Denmark's Dako shows once again why molecular diagnostics are the life sciences segment to watch this year. Agilent Technologies ($A) has inked a deal to pay $2.2 billion for the cancer diagnostic tools company in a bid to boost its growth in the space.
POPULAR COMMENT THREADS